Skip to main content

TCG Crossover — Portfolio, Page 4

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

81
Companies
$14.3B
Total invested
$176.4M
Avg. check
10
Industries
Biotechnology 9Medical 6Health Care 4Therapeutics 4Pharmaceutical 4Life Science 2+4 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 73–81 of 81
Entrada Therapeutics
June 2024

Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.

Biotechnology · Boston$100.0M Post Ipo Equity
Tourmaline Bio
January 2024

Tourmaline Bio is a biotechnology company that develops medicines to treat inflammatory and immune diseases in patients.

Biotechnology · New York$172.5M Post Ipo Equity
Alpine Immune Sciences
November 2023

Alpine Immune Sciences is an immunotherapy company focused on developing treatments for autoimmune and inflammatory diseases.

Biotechnology · Seattle$150.0M Post Ipo Equity
Upstream Bio
June 2023

Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma.

Biotechnology · Waltham$200.0M Series B
Alkeus Pharmaceuticals
June 2023

Alkeus Pharmaceuticals is a Boston-based startup focused on treatments for serious ophthalmic conditions.

Biotechnology · Cambridge$150.0M Series B
Synthekine
January 2023

Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific and potent cytokine therapies.

Biotechnology · Menlo Park$100.0M Series C
RayzeBio
September 2022

RayzeBio is a pharmaceuticals company that develops targeted radiopharmaceutical drugs for cancer.

Biotechnology · San Diego$160.0M Series D
Versanis Bio
August 2021

Versanis Bio discovers and develops medicines that address medical conditions prevalent in older adults.

Biotechnology · Oakland$70.0M Series A
Magenta Therapeutics
May 2021

Magenta Therapeutics is a new biotechnology company developing therapeutics that unlock the power of stem cell biology.

Biotechnology · Cambridge$86.4M Post Ipo Equity

Where TCG Crossover invests

Biotechnology9
Medical6
Health Care4
Therapeutics4
Pharmaceutical4
Life Science2

About TCG Crossover's portfolio

How many companies has TCG Crossover invested in?▸

TCG Crossover has invested in 81 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does TCG Crossover invest in?▸

TCG Crossover's top investment sectors include Biotechnology, Medical, Health Care, Therapeutics, Pharmaceutical. The firm invests across 10 different industry categories.

What is TCG Crossover's largest investment?▸

Among tracked funding rounds, Upstream Bio received $200.0M in a Series B round. TCG Crossover's total known invested capital is $14.3B.

What is the average investment size for TCG Crossover?▸

TCG Crossover's average investment size is $176.4M across its portfolio of 81 companies.

What are TCG Crossover's most recent investments?▸

Recent TCG Crossover portfolio additions include Entrada Therapeutics, Tourmaline Bio, Alpine Immune Sciences, Upstream Bio, Alkeus Pharmaceuticals. These companies were founded in 2020 or later.

Reach the founders behind these 81 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →